Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Celgene and Sutro Biopharma reorganise immuno-oncology collaboration

Celgene and Sutro Biopharma reorganise immuno-oncology collaboration

14th August 2017

Celgene and Sutro Biopharma have announced that they will be reorganising the immuno-oncology collaboration they originally launched in 2014.

The companies' work will be refocused to target four programmes that are advancing through preclinical development, including an antibody drug conjugate (ADC) programme targeting B-cell maturation antigen (BCMA) previously disclosed by Celgene.

Sutro may also produce both GLP and cGMP material as the BCMA ADC programme progresses, with these projects coming in addition to work on the non-Hodgkin lymphoma and multiple myeloma therapy STRO-001 and the platinum-resistant ovarian cancer drug STR0-002.

Bill Newell, chief executive officer of Sutro Biopharma, said: "With this revised agreement, Celgene continues to support Sutro's development, while we can move rapidly into development of multiple product candidates and evaluate new opportunities for partnerships and funding."

Under the original 2014 agreement, Celgene had worldwide rights to the first collaboration programme to reach investigational new drug status. The newly-modified deal gives Celgene worldwide rights to a second collaboration programme.

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.ADNFCR-8000103-ID-801838885-ADNFCR

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.